Work

Abstract B009: Trial in Progress: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/ Amplified Gastric/ Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression

Year: 2025

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-25-b009

Authors: Alexandria M. Doerfler, Ecaterina E. Dumbrava, Ying Yuan, Cheryl Pickett-Gies, Steven Gore, Shannon N. Westin, Jaffer A. Ajani, Ann-Marie Cimo, Siqing Fu, Catherine Lee, Quan Lin, Ronald Fleming, Timothy A. Yap, Khandan Keyomarsi, Funda Meric-Bernstam

Institutions: The University of Texas MD Anderson Cancer Center, National Cancer Institute, Zentalis Pharmaceuticals (United States), Daiichi Sankyo (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7093326607

Cites:

Cited by: 1

Related to: